BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs 2021;26:149-63. [PMID: 33856246 DOI: 10.1080/14728214.2021.1918099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Oakley F. Interrogating mechanisms of liver fibrosis with omics. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34903888 DOI: 10.1038/s41575-021-00567-6] [Reference Citation Analysis]
2 Ma J, Zhao Q, Chen M, Wang W, He B, Jiang Y, Li Y. microRNA-122 inhibits hepatic stellate cell proliferation and activation in vitro and represses carbon tetrachloride-induced liver cirrhosis in mice. Ann Hepatol 2022;:100700. [PMID: 35338010 DOI: 10.1016/j.aohep.2022.100700] [Reference Citation Analysis]
3 Brennan PN, MacMillan M, Manship T, Moroni F, Glover A, Graham C, Semple S, Morris DM, Fraser AR, Pass C, McGowan NWA, Turner ML, Lachlan N, Dillon JF, Campbell JDM, Fallowfield JA, Forbes SJ. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open 2021;11:e053190. [PMID: 34750149 DOI: 10.1136/bmjopen-2021-053190] [Reference Citation Analysis]
4 Ramos MJ, Bandiera L, Menolascina F, Fallowfield JA. In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. iScience 2022;25:103549. [PMID: 34977507 DOI: 10.1016/j.isci.2021.103549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Akbari B, Baghaei-Yazdi N, Bahmaie M, Mahdavi Abhari F. The role of plant-derived natural antioxidants in reduction of oxidative stress. Biofactors 2022. [PMID: 35229925 DOI: 10.1002/biof.1831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]